PARP1 and triple-negative breast carcinoma: According to the treatment guidelines for advanced triple negative breast cancer (TNBC), patients are only eligible for treatment with the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib after undergoing first-line systemic non-targeted chemotherapy, and only if they carry a BRCA1/2 mutation [6].